12:00 AM
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Flibanserin regulatory update

Sprout said it resubmitted an NDA to FDA earlier this year for flibanserin to treat hypoactive sexual desire disorder (HSDD). The company, which expects a decision on the application by year end, acquired the serotonin (5-HT1A) receptor agonist and...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >